智通财经APP讯，嘉事堂(002462.SZ)发布公告，公司于2026年1月27日接到股东中国光大实业(集团)有 限责任公司(以下简称"光大实业")书面通知，光大实业及子公司中国光大医疗健康产业有限公司正在筹 划公司股权转让事宜，该事项可能导致公司控股股东、实际控制人发生变更。 经公司向深圳证券交易所申请，公司股票自2026年1月28日(星期三)开市起停牌，预计停牌时间不超过2 个交易日。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 责任编辑：杨红卜 登录新浪财经APP 搜索【信披】查看更多考评等级 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：资本秘闻 筹划控制权变更，嘉事堂（002462）1月28日起停牌。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：资本秘闻 筹划控制权变更，嘉事堂（002462）1月28日起停牌。 1月27日晚间，嘉事堂发布公告称，公司于1月27日接到股东中国光大实业（集团）有限责任公司（以下 简称"光大实业"）书面通知，光大实业及子公司中国光大医疗健康产业有限公司正在筹划公司股权转让 事宜，该事项可能导致公司控股股东、实际控制人发生变更。 嘉事堂表示，鉴于本次交易事项目前尚存在不确定性，为保证公平信息披露、维护公司全体股东利益， 根据相关规定，经公司向深交所申请，公司股票自1月28日开市起停牌，预计停牌时间不超过2个交易 日。 责任编辑：杨红卜 1月27日晚间，嘉事堂发布公告称，公司于1月27日接到股东中国光大实业（集团）有限责任公司（以下 简称"光大实业"）书面通知，光大实业及子公司中国光大医 ...

嘉事堂于2026年1月27日接到股东中国光大实业(集团)有限责任公司(以下简称"光大实业")书面通知，光 大实业及子公司中国光大医疗健康产业有限公司正在筹划嘉事堂股权转让事宜，该事项可能导致嘉事堂 控股股东、实际控制人发生变更。 根据嘉事堂披露的2024年年度报告，该公司控股股东为中国光大医疗健康产业有限公司，实际控制人为 中国光大集团股份公司。 嘉事堂表示，鉴于本次交易事项目前尚存在不确定性，为保证公平信息披露、维护公司全体股东利益， 根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第6号——停复牌》等 相关规定，经公司向深圳证券交易所申请，公司股票(股票代码：002462，股票简称：嘉事堂)自2026年 1月28日(星期三)开市起停牌，预计停牌时间不超过2个交易日。 嘉事堂表示，股票停牌期间，公司将根据上述事项进展情况，严格按照有关法律法规的规定和要求履行 信息披露义务。待上述事项确定后，公司将及时发布相关公告并申请公司股票复牌。本次交易事项目前 尚存在重大不确定性，敬请广大投资者注意投资风险。 中国经济网北京1月27日讯嘉事堂（002462）(002462.SZ)今日晚间发布关于筹 ...

嘉事堂表示，鉴于本次交易事项目前尚存在不确定性，为保证公平信息披露、维护公司全体股东利益， 根据相关规定，经公司向深交所申请，公司股票自1月28日开市起停牌，预计停牌时间不超过2个交易 日。 北京商报讯（记者 丁宁）1月27日晚间，嘉事堂（002462）发布公告称，公司于1月27日接到股东中国 光大实业（集团）有限责任公司（以下简称"光大实业"）书面通知，光大实业及子公司中国光大医疗健 康产业有限公司正在筹划公司股权转让事宜，该事项可能导致公司控股股东、实际控制人发生变更。 ...

每经AI快讯，嘉事堂1月27日晚间发布公告称，嘉事堂药业股份有限公司于2026年1月27日接到股东中 国光大实业（集团）有限责任公司书面通知，光大实业及子公司中国光大医疗健康产业有限公司正在筹 划公司股权转让事宜，该事项可能导致公司控股股东、实际控制人发生变更。 每经头条（nbdtoutiao）——从极寒测试到万套装车！半固态电池今年有望搭载多款新车：各大厂商摩 拳擦掌，动力电池技术迎来迭代年 （记者 王晓波） 鉴于本次交易事项目前尚存在不确定性，为保证公平信息披露、维护公司全体股东利益，经公司向深圳 证券交易所申请，公司股票（股票代码：002462，股票简称：嘉事堂）自2026年1月28日（星期三）开 市起停牌，预计停牌时间不超过2个交易日。 ...

Suspension and Resumption - Jiasitang's shareholder, Everbright Industrial, is planning a transfer of company shares, leading to a stock suspension [1] Share Buyback - Pianzaihuang's controlling shareholder, Jiulongjiang Group, intends to increase its stake in the company by 300 million to 500 million yuan. The Phase I clinical trial of the innovative drug PZH2113 has completed the enrollment of the first subject, with no similar indication drugs approved in the domestic and international markets [2] Mergers and Acquisitions - Tailinwei plans to acquire 100% equity of Panqi Micro through a combination of issuing shares and cash payment [3] Business Operations - Baitong Energy plans to invest approximately 400 million USD through its wholly-owned subsidiary, Tuda Aluminum, in a project with Angola's Dande Port Development Company, establishing a wholly-owned company, Baitong Tuda (Angola) Aluminum [4] - Puluo Pharmaceutical has signed a strategic cooperation framework agreement with Hangzhou Derui Zhiyao Technology Co., Ltd. to develop a long-term collaboration on CDMO projects [4] - Nord shares intend to upgrade and transform the production line equipment of its wholly-owned subsidiary, Qinghai Electronics, with an estimated total investment of 168 million yuan, expanding production capabilities to include high-end lithium battery copper foil [4] Performance Changes - Guotai Haitong expects a net profit of 27.533 billion to 28.006 billion yuan for 2025, representing a year-on-year increase of 111% to 115%, driven by significant growth in wealth management, institutional, and trading business revenues [5] - Shenwan Hongyuan anticipates a net profit of 9.1 billion to 10.1 billion yuan for 2025, a year-on-year growth of 75% to 94% [6] - Yahua Group projects a net profit of 600 million to 680 million yuan for 2025, reflecting a year-on-year increase of 133.36% to 164.47%, supported by stable orders from high-quality clients and a rebound in lithium salt market prices [6] - Ganfeng Lithium expects a net profit of 1.1 billion to 1.65 billion yuan for 2025, marking a turnaround from losses [7] - Zhongjin Gold anticipates a net profit of 4.8 billion to 5.4 billion yuan for 2025, a year-on-year increase of 41.76% to 59.48%, primarily due to improved profitability in its mineral gold business [7] - Nanya New Materials expects a net profit of 220 million to 260 million yuan for 2025, a year-on-year growth of 337.20% to 416.69%, driven by a recovery in demand in the copper-clad laminate industry [7] - Shijia Photon anticipates a net profit of approximately 342 million yuan for 2025, reflecting a year-on-year increase of about 425.95%, supported by rapid growth in the data communication market driven by AI development [7] - Zhenlei Technology projects a net profit of 123 million to 145 million yuan for 2025, a year-on-year increase of 529.64% to 642.26%, benefiting from increased demand in the special integrated circuit industry [8] - Yihua shares expect a net profit of 310 million to 390 million yuan for 2025, a year-on-year growth of 149.66% to 214.09%, driven by the development of the computing power industry [8] - Electric Investment and Financing anticipates a net profit of 3 billion to 3.5 billion yuan for 2025, a year-on-year increase of 187.37% to 235.26%, due to the inclusion of Electric Investment Nuclear Power in the consolidated financial statements following a major asset restructuring [8] - Hongxin Electronics expects a net profit of 110 million to 150 million yuan for 2025, a year-on-year increase of 93.61% to 164.01%, with profitability in its FPC business and rapid growth in computing power business driven by the ALL IN AI strategy [8] - Shennan Circuit anticipates a net profit of 3.154 billion to 3.342 billion yuan for 2025, a year-on-year increase of 68% to 78% [8] - Hudian shares expect a net profit of 3.822 billion yuan for 2025, a year-on-year increase of 48% [8]

(本文来自第一财经) 嘉事堂公告，公司于2026年1月27日接到股东中国光大实业（集团）有限责任公司书面通知，光大实业 及子公司中国光大医疗健康产业有限公司正在筹划公司股权转让事宜，该事项可能导致公司控股股东、 实际控制人发生变更。公司股票自2026年1月28日开市起停牌，预计停牌时间不超过2个交易日。 ...

证券代码：002462 证券简称：嘉事堂 公告编号： 2026-02 嘉事堂药业股份有限公司 关于筹划控制权变更事项的停牌公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、公司股票于 2026 年 1 月 28 日（星期三）开市起停牌，预计停牌时间不 超过 2 个交易日。 2、本次交易事项目前尚存在重大不确定性，敬请广大投资者注意投资风险。 特此公告。 嘉事堂药业股份有限公司 董 事 会 2026 年 1 月 28 日 嘉事堂药业股份有限公司（以下简称"公司"）于 2026 年 1 月 27 日接到股 东中国光大实业（集团）有限责任公司（以下简称"光大实业"）书面通知， 光大实业及子公司中国光大医疗健康产业有限公司正在筹划公司股权转让事宜， 该事项可能导致公司控股股东、实际控制人发生变更。 鉴于本次交易事项目前尚存在不确定性，为保证公平信息披露、维护公司 全体股东利益，根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公 司自律监管指引第 ...

Group 1 - The core viewpoint of the news is that 嘉事堂's stock has experienced fluctuations, with a recent decline of 2.02% and a current price of 16.50 yuan per share, while the company has seen a year-to-date increase of 14.90% [1] - As of January 9, 嘉事堂's shareholder count has increased by 50% to 36,000, while the average circulating shares per person decreased by 33.33% to 8,096 shares [2] - 嘉事堂's main business involves pharmaceutical wholesale and retail, with commercial revenue accounting for 100% of its income [1] Group 2 - For the period from January to September 2025, 嘉事堂 reported a revenue of 14.459 billion yuan, representing a year-on-year decrease of 21.80%, and a net profit attributable to shareholders of 141 million yuan, down 38.81% year-on-year [2] - 嘉事堂 has been listed on the stock market since August 18, 2010, and has distributed a total of 874 million yuan in dividends since its A-share listing, with 216 million yuan distributed in the last three years [2] - The company operates within the pharmaceutical and biological industry, specifically in the pharmaceutical commercial sector, and is involved in various concept sectors including pharmaceutical e-commerce and state-owned enterprise reform [2]

Market Performance - The pharmaceutical commercial sector increased by 0.94% on January 22, with Huaren Health leading the gains [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Individual Stock Performance - Huaren Health (301408) closed at 23.17, up 6.24% with a trading volume of 347,100 shares and a transaction value of 781 million [1] - Jiyu Pingmin (301017) closed at 17.71, up 4.67% with a trading volume of 188,800 shares and a transaction value of 328 million [1] - Mushi Tang (002462) closed at 16.89, up 4.65% with a trading volume of 205,900 shares and a transaction value of 344 million [1] - Other notable stocks include Yizheng Medical (002788) up 3.14% and Dajia Weikang (301126) up 3.11% [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 82.14 million from institutional investors, while retail investors saw a net inflow of 5.87 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are entering the market [2] Detailed Capital Flow for Selected Stocks - Jiyu Pingmin had a net inflow of 20.13 million from institutional investors, while retail investors had a net outflow of 40.72 million [3] - Huaren Health saw a net inflow of 28.31 million from institutional investors and a net outflow of 60.37 million from retail investors [3] - Mushi Tang had a net inflow of 42.17 million from institutional investors, but retail investors experienced a net outflow of 43.09 million [3]